Gene expression profiling analysis reveals arsenic-induced cell cycle arrest and apoptosis in p53-proficient and p53-deficient cells through differential gene pathways

Toxicology and Applied Pharmacology

Volumn 233, Issue 3, 2008, Pages 389-403

  Yu, Xiaozhong ^a   Robinson, Joshua F ^a   Gribble, Elizabeth ^a   Hong, Sung Woo ^a   Sidhu, Jaspreet S ^a   Faustman, Elaine M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Apoptosis and oxidative stress; Arsenite Arsenic; Cell cycle regulation; Gene expression profiling; p53

Indexed keywords

ARSENIC; ARSENIC TRIOXIDE; CASPASE 3; PROTEIN P53; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CONCENTRATION RESPONSE; DNA DAMAGE; DRUG MECHANISM; EMBRYO; ENZYME INDUCTION; FIBROBLAST; GENE; GENE EXPRESSION PROFILING; GENOMICS; GENOTYPE; MOUSE; NONHUMAN; NOXA GENE; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANIMALS; APOPTOSIS; ARSENITES; CELL CYCLE; CELLS, CULTURED; DNA DAMAGE; ENVIRONMENTAL POLLUTANTS; FIBROBLASTS; GENE EXPRESSION; GENE EXPRESSION PROFILING; MICE; NF-E2-RELATED FACTOR 2; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 56249134894     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.09.016     Document Type: Article

References (57)

1. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., Eppig J.T., Harris M.A., Hill D.P., Issel-Tarver L., Kasarskis A., Lewis S., Matese J.C., Richardson J.E., Ringwald M., Rubin G.M., and Sherlock G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25 (2000) 25-29
2. Attardi L.D., Reczek E.E., Cosmas C., Demicco E.G., McCurrach M.E., Lowe S.W., and Jacks T. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev. 14 (2000) 704-718
3. Bode A.M., and Dong Z. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit. Rev. Oncol. Hematol. 42 (2002) 5-24
4. Borenfreund E., and Puerner J. Toxicity determined in vitro by morphological alterations and neurtral red absorption. Toxicol. Lett. 24 (1985) 119-124
5. Chan K., Han X.D., and Kan Y.W. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4611-4616
6. Chen G.Q., Shi X.G., Tang W., Xiong S.M., Zhu J., Cai X., Han Z.G., Ni J.H., Shi G.Y., Jia P.M., Liu M.M., He K.L., Niu C., Ma J., Zhang P., Zhang T.D., Paul P., Naoe T., Kitamura K., Miller W., Waxman S., Wang Z.Y., de The H., Chen S.J., and Chen Z. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89 (1997) 3345-3353
7. Chen F., Lu Y., Zhang Z., Vallyathan V., Ding M., Castranova V., and Shi X. Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J. Biol. Chem. 276 (2001) 11414-11419
8. Dahlquist K.D., Salomonis N., Vranizan K., Lawlor S.C., and Conklin B.R. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat. Genet. 31 (2002) 19-20
9. Doniger S.W., Salomonis N., Dahlquist K.D., Vranizan K., Lawlor S.C., and Conklin B.R. MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol. 4 (2003) R7
10. Enomoto A., Itoh K., Nagayoshi E., Haruta J., Kimura T., O'Connor T., Harada T., and Yamamoto M. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci. 59 (2001) 169-177
11. FDA (2000). FDA approves arsenic trioxide for leukemia treatment in record time for a cancer drug development program., pp. http://www.fda.gov/bbs/topics/ANSWERS/ANS01040.html. Food and Drug Administration U.S. Department of Health and Human Services Public Health Service 5600 Fishers Lane Rockville, MD 20857.
12. Gribble E.J., Hong S.W., and Faustman E.M. The magnitude of methylmercury-induced cytotoxicity and cell cycle arrest is p53-dependent. Birth Defects Res. Part A-Clin. Mol. Teratol. 73 (2005) 29-38
13. Heinrich P.C., Castell J.V., and Andus T. Interleukin-6 and the acute phase response. Biochem. J. 265 (1990) 621-636
14. Huang S.C., and Lee T.C. Arsenite inhibits mitotic division and perturbs spindle dynamics in HeLa S3 cells. Carcinogenesis 19 (1998) 889-896
15. Huang C., Ma W.Y., Li J., and Dong Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res. 59 (1999) 3053-3058
16. Kho P.S., Wang Z., Zhuang L., Li Y., Chew J.L., Ng H.H., Liu E.T., and Yu Q. p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J. Biol. Chem. 279 (2004) 21183-21192
17. Kitchin K.T. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol. 172 (2001) 249-261
18. Komarova E.A., Krivokrysenko V., Wang K., Neznanov N., Chernov M.V., Komarov P.G., Brennan M.L., Golovkina T.V., Rokhlin O.W., Kuprash D.V., Nedospasov S.A., Hazen S.L., Feinstein E., and Gudkov A.V. p53 is a suppressor of inflammatory response in mice. FASEB J. 19 (2005) 1030-1032
19. Kurzrock R. Cytokine deregulation in cancer. Biomed. Pharmacother. 55 (2001) 543-547
20. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Lerner J., Brunet J.P., Subramanian A., Ross K.N., Reich M., Hieronymus H., Wei G., Armstrong S.A., Haggarty S.J., Clemons P.A., Wei R., Carr S.A., Lander E.S., and Golub T.R. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313 (2006) 1929-1935
21. Liang X.Q., Cao E.H., Zhang Y., and Qin J.F. A P53 target gene, PIG11, contributes to chemosensitivity of cells to arsenic trioxide. FEBS Lett. 569 (2004) 94-98
22. Litzow M.R. Arsenic trioxide. Expert Opin. Pharmacother. 9 (2008) 1773-1785
23. Liu Q., Hilsenbeck S., and Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101 (2003) 4078-4087
24. Luderer U., Diaz D., Faustman E.M., and Kavanagh T.J. Localization of glutamate cysteine ligase subunit mRNA within the rat ovary and relationship to follicular apoptosis. Mol. Reprod. Dev. 65 (2003) 254-261
25. McCabe Jr. M.J., Singh K.P., Reddy S.A., Chelladurai B., Pounds J.G., Reiners Jr. J.J., and States J.C. Sensitivity of myelomonocytic leukemia cells to arsenite-induced cell cycle disruption, apoptosis, and enhanced differentiation is dependent on the inter-relationship between arsenic concentration, duration of treatment, and cell cycle phase. J. Pharmacol. Exp. Ther. 295 (2000) 724-733
26. Miller Jr. W.H., Schipper H.M., Lee J.S., Singer J., and Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 62 (2002) 3893-3903
27. Moi P., Chan K., Asunis I., Cao A., and Kan Y.W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 9926-9930
28. Negrier S., Perol D., Menetrier-Caux C., Escudier B., Pallardy M., Ravaud A., Douillard J.Y., Chevreau C., Lasset C., and Blay J.Y. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J. Clin. Oncol. 22 (2004) 2371-2378
29. O'Reilly M.A., Staversky R.J., Watkins R.H., Maniscalco W.M., and Keng P.C. p53-independent induction of GADD45 and GADD153 in mouse lungs exposed to hyperoxia. Am. J. Physiol., Lung Cell. Mol. Physiol. 278 (2000) L552-559
30. Ogata H., Goto S., Sato K., Fujibuchi W., Bono H., and Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 27 (1999) 29-34
31. Ohkusu-Tsukada K., Tsukada T., and Isobe K. Accelerated development and aging of the immune system in p53-deficient mice. J. Immunol. 163 (1999) 1966-1972
32. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., and Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19 (2002) 607-614
33. Park W.H., Seol J.G., Kim E.S., Hyun J.M., Jung C.W., Lee C.C., Kim B.K., and Lee Y.Y. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 60 (2000) 3065-3071
34. Pelicano H., Feng L., Zhou Y., Carew J.S., Hileman E.O., Plunkett W., Keating M.J., and Huang P. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem. 278 (2003) 37832-37839
35. Prestera T., Talalay P., Alam J., Ahn Y.I., Lee P.J., and Choi A.M. Parallel induction of heme oxygenase-1 and chemoprotective phase 2 enzymes by electrophiles and antioxidants: regulation by upstream antioxidant-responsive elements (ARE). Mol. Med. 1 (1995) 827-837
36. Puthalakath H., and Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 9 (2002) 505-512
37. Qian Y., Castranova V., and Shi X. New perspectives in arsenic-induced cell signal transduction. J. Inorg. Biochem. 96 (2003) 271-278
38. Ramos-Gomez M., Dolan P.M., Itoh K., Yamamoto M., and Kensler T.W. Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. Carcinogenesis 24 (2003) 461-467
39. Saeed A.I., Sharov V., White J., Li J., Liang W., Bhagabati N., Braisted J., Klapa M., Currier T., Thiagarajan M., Sturn A., Snuffin M., Rezantsev A., Popov D., Ryltsov A., Kostukovich E., Borisovsky I., Liu Z., Vinsavich A., Trush V., and Quackenbush J. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34 (2003) 374-378
40. Salazar A.M., Ostrosky-Wegman P., Menendez D., Miranda E., Garcia-Carranca A., and Rojas E. Induction of p53 protein expression by sodium arsenite. Mutat. Res. 381 (1997) 259-265
41. Shen L., Chen T.X., Wang Y.P., Lin Z., Zhao H.J., Zu Y.Z., Wu G., and Ying D.M. As2O3 induces apoptosis of the human B lymphoma cell line MBC-1. J. Biol. Regul. Homeost. Agents 14 (2000) 116-119
42. Sidhu J.S., Ponce R.A., Vredevoogd M.A., Yu X., Gribble E., Hong S.W., Schneider E., and Faustman E.M. Cell cycle inhibition by sodium arsenite in primary embryonic rat midbrain neuroepithelial cells. Toxicol. Sci. 89 (2005) 475-484
43. Tapio S., and Grosche B. Arsenic in the aetiology of cancer. Mutat. Res. 612 (2006) 215-246
44. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5116-5121
45. Vairapandi M., Azam N., Balliet A.G., Hoffman B., and Liebermann D.A. Characterization of MyD118, Gadd45, and proliferating cell nuclear antigen (PCNA) interacting domains. PCNA impedes MyD118 AND Gadd45-mediated negative growth control. J. Biol. Chem. 275 (2000) 16810-16819
46. Vengellur A., Woods B.G., Ryan H.E., Johnson R.S., and LaPres J.J. Gene expression profiling of the hypoxia signaling pathway in hypoxia-inducible factor 1alpha null mouse embryonic fibroblasts. Gene Expr. 11 (2003) 181-197
47. Villunger A., Michalak E.M., Coultas L., Mullauer F., Bock G., Ausserlechner M.J., Adams J.M., and Strasser A. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302 (2003) 1036-1038
48. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
49. Wang X.W., Zhan Q., Coursen J.D., Khan M.A., Kontny H.U., Yu L., Hollander M.C., O'Connor P.M., Fornace Jr. A.J., and Harris C.C. GADD45 induction of a G2/M cell cycle checkpoint. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3706-3711
50. Wright G.W., and Simon R.M. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19 (2003) 2448-2455
51. Yan B., Chen G., Saigal K., Yang X., Jensen S.T., Van Waes C., Stoeckert C.J., and Chen Z. Systems biology-defined NF-kappaB regulons, interacting signal pathways and networks are implicated in the malignant phenotype of head and neck cancer cell lines differing in p53 status. Genome Biol. 9 (2008) R53
52. Yi J., Yang J., He R., Gao F., Sang H., Tang X., and Ye R.D. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res. 64 (2004) 108-116
53. Yih L.H., and Lee T.C. Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts. Cancer Res. 60 (2000) 6346-6352
54. Yih L.H., Peck K., and Lee T.C. Changes in gene expression profiles of human fibroblasts in response to sodium arsenite treatment. Carcinogenesis 23 (2002) 867-876
55. Yu X., Sidhu J.S., Hong S., and Faustman E.M. Essential role of extracellular matrix (ECM) overlay in establishing the functional integrity of primary neonatal rat Sertoli cell/gonocyte co-cultures: an improved in vitro model for assessment of male reproductive toxicity. Toxicol. Sci. 84 (2005) 378-393
56. Yu X., Sidhu J.S., Robinson J.F., Hong S., and Faustman E.M. Integrative analysis of genome-wide gene expression and pathway mapping in mouse embryonic fibroblasts (MEFs) exposed to cadmium, arsenic and methylmercury: Induction of oxidative stress, disruption of ubiquitin-proteasome system and cell cycle regulation. The Toxicologist 237 (2005)
57. Yu X., Griffith W.C., Hanspers K., Dillman III J.F., Ong H., Vredevoogd M.A., and Faustman E.M. A system-based approach to interpret dose- and time-dependent microarray data: quantitative integration of gene ontology analysis for risk assessment. Toxicol. Sci. 92 (2006) 560-577